


What is claimed is:

1-62. Cancelled.

63. (Previously presented) A compound according to formula A:



Wherein each Y is independently O or is absent;

Each (Z) is independently H, an optionally substituted C₁-C₄ alkyl group, an optionally substituted aryl group or an optionally substituted heterocycle;

B is Y(Z) or together with C forms a bond between the two phenyl rings to which each of B and C is attached;

C is Y(Z) or together with B forms a bond between the two phenyl rings to which each of B and C is attached;

R₅ is OH, a -OC(O)R_x group, a -C(O)R_x group, or a -C(O)OR_x group, where R_x is a C₂ to C₁₅ alkyl group, or together with T forms a double bond;

R₁ is H or a C₁-C₄ alkyl;

R₂ is H or a C₁-C₄ alkyl when R₅ is a -OC(O)R_x group, a -C(O)R_x group, or a -C(O)OR_x group, and R₂ is H or a C₂-C₄ alkyl group when R₅ is OH;

(U) is H, an optionally substituted C₁-C₄ alkyl group, an optionally substituted aryl group, an optionally substituted heterocycle or together with W or T forms a double bond when Y is absent;

T is H or forms a double bond with R₅ or with Y(U) when Y is absent;

W is H or forms a double bond with Y(U) when Y is absent;


R₄ is H, OH, a carboxylate group, a -OC(O)R_x group, a -C(O)R_x, or a -C(O)OR_x group, where R_x is a C₂ to C₁₅ alkyl group;

R⁶ is H, OH, a carboxylate group, a -OC(O)R_x group, a -C(O)R_x, or a -C(O)OR_x group, where R_x is defined above; and

n is 1 or 2,

or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

64. (Previously presented) A compound according to claim 1 wherein B and C form a bond according to the structure:



65. (Previously presented) A compound according to claim 64 wherein R₅ is OH, R₄ is H and R₆ is H, or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

66. (Previously presented) A compound according to claim 64 wherein T is H or forms a double bond with (U) and B and C form a bond.

67. (Previously presented) A compound according to claim 65 wherein T forms a double bond with (U).

68. (Previously presented) A compound according to claim 64 wherein R_1 is H or CH_3 , each (Z) is independently H or CH_3 , R_4 is H and R_6 is H or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

69. (Previously presented) A compound according to claim 67 wherein R_1 is independently H or CH_3 and each (Z) is independently H or CH_3 , or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

70. (Previously presented) A compound according to claim 65 wherein R_1 is CH_3 .

71. (Previously presented) A compound according to claim 66 wherein R_1 is CH_3 .

72. (Previously presented) A compound according to claim 67 wherein R_1 is CH_3 .

73. (Previously presented) A compound according to claim 65 wherein each (Z) is CH_3 .

74. (Previously presented) A compound according to claim 66 wherein each (Z) is CH_3 .

75. (Previously presented) A compound according to claim 67 wherein each (Z) is CH_3 .


76. (Previously presented) A compound according to claim 65 wherein R_1 is H.

77. (Previously presented) A compound according to claim 66 wherein R_1 is H.

78. (Previously presented) A compound according to claim 67 wherein one of R_1 is H.


79. (Previously presented) A compound according to claim 75 wherein one of R_1 is H.

80. (Currently amended) A compound according to claim 64 having the formula:




or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

81. (Previously presented) A compound according to claim 64 having the formula:




or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

82. (Previously presented) A compound of claim 64, wherein the compound has the formula:




or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

83. (Previously presented) A compound of claim 64, wherein the compound has the formula:



or its enantiomer or pharmaceutically acceptable salt thereof.

84. (Previously presented) A compound of the formula:



wherein Y is O, S, NH, CH₂ or is absent;

X is H or OR_b, where R_b is H, an optionally substituted C₁-C₄ alkyl, an optionally substituted aryl or an optionally substituted heterocycle;


R_1 , R_2 , R_3 , R_4 and R_7 are the same or different and are either H, an optionally substituted C_1 - C_4 alkyl, an optionally substituted aryl, or an optionally substituted heterocycle, or a substituted heterocycle;

R_{5a} is H, OH, a $-OC(O)R_x$ group, a $-C(O)R_x$, or a $-C(O)OR_x$ group, where R_x is a C_2 to C_{15} alkyl group;

R_6 is H, OH, a carboxyl group, a $-OC(O)R_x$ group, a $-C(O)R_x$, or a $-C(O)OR_x$ group, where R_x is defined above,

or an epimer or pharmaceutically acceptable salt thereof.


85. (Previously presented) A compound of claim 84 according to the structure:




where X is H, OH, $O(C_1-C_4)$ alkyl or O-benzyl,

or an epimer or pharmaceutically acceptable salt thereof.

86. (Previously presented) A compound of claim 84, wherein the compound has the formula:






where R_7 is H or

and where R_a is H, an optionally substituted C_1 - C_4 alkyl, an optionally substituted aryl or an optionally substituted heterocycle,
or an epimer or pharmaceutically acceptable salt thereof.

87. (Previously presented) A compound of claim 83, wherein the compound has the formula:




where R_d is H or a C_1 - C_4 alkyl group,

or an epimer or pharmaceutically acceptable salt thereof.

88. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to any of claims 63-87.

89. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to the formula:



Wherein each Y is independently O or is absent;

Each (Z) is independently H, an optionally substituted C₁-C₄ alkyl group, an optionally substituted aryl group or an optionally substituted heterocycle;

B is Y(Z) or together with C forms a bond between the two phenyl rings to which each of B and C is attached;

C is Y(Z) or together with B forms a bond between the two phenyl rings to which each of B and C is attached;

R₁ is H or a C₁-C₄ alkyl;

R₂ is H or a C₁-C₄ alkyl;

(U) is H, an optionally substituted C₁-C₄ alkyl group, an optionally substituted aryl group, an optionally substituted heterocycle or together with W or T forms a double bond when Y is absent;

T is H or forms a double bond with R₅ or with Y(U) when Y is absent;

W is H or forms a double bond with Y(U) when Y is absent;


R₄ is H, OH, a carboxylate group, a -OC(O)R_x group, a -C(O)R_x, or a -C(O)OR_x group, where R_x is a C₂ to C₁₅ alkyl group;

R₅ is OH, a -OC(O)R_x group, a -C(O)R_x group, or a -C(O)OR_x group, where R_x is a C₂ to C₁₅ alkyl group, or together with T forms a double bond;

R₆ is H, OH, a carboxylate group, a -OC(O)R_x group, a -C(O)R_x, or a -C(O)OR_x group, where R_x is defined above;


n is 1 or 2, or an epimer, enantiomer or pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.

90. (Previously presented) A composition of claim 89 wherein said compound has the formula




or an epimer, enantiomer or pharmaceutically acceptable salt thereof.

91. (Previously presented) A composition of claim 89, wherein the compound has the formula:



or a pharmaceutically acceptable salt thereof.


92. (Previously presented) A composition of claim 89, wherein the compound has the formula:




or an enantiomer or pharmaceutically acceptable salt thereof.

93. (Previously presented) A process of making a tyloindicine analogue comprising:

(a) effecting a Martin sulfurane dehydration of an alcohol of the formula:



to yield an alkene of the formula



; and

(b) reducing the alkene of step (a) in a reducing reaction medium to yield a tyloindicine analogue of the formula

